For 30 advance/early chapters : p atreon.com/AutumnXd
The articles started appearing online before Ryan had finished dinner.
Some were filed by reporters who had attended the launch in person. Others were from journalists who had interviewed civilians outside the showcase galleries. A few had attempted to reach the flagship fitting center, found it impossible to enter due to the crowd, and filed dispatches from the sidewalk.
Erik Donovan's piece for NPBN was the standout.
His headline: *"Prism Sciences' Triton-1 Launch: Glimpsing the Future We've Been Waiting For."*
Erik had done the work. The article walked through every claim made at the launch event and verified them against industry baselines. It included a long-form profile of Daniel Grant and his story of regaining function after a decade without a prosthetic. It dedicated three paragraphs to the price comparison, with a chart showing Triton-1's $23,000 ceiling against industry-standard pricing for full-arm prosthetics. The chart made the financial argument unmistakable.
Erik openly speculated that Prism Sciences could not be recouping its R&D costs at this price point. He was the first reporter to publicly raise the question, and several other outlets immediately picked up the framing.
He compared the technology architectures directly: Triton-1's non-invasive cortical signal acquisition versus the targeted muscle reinnervation approach used by Helios's Angel and NeuraPath's domestic offering. The conclusion landed without ambiguity: the surgical approach was about to be obsolete.
The article closed with a paragraph on the holographic projector technology, noting that Prism Sciences had quietly debuted a second industry-shifting capability as corridor decoration. Erik's framing: "Prism Sciences appears to have multiple game-changing technologies in its portfolio. Today's launch is the first product. The pace at which the company chooses to release the others will define the next decade of consumer technology."
Pat Conrad's competing piece took a similar angle but with more business-press flavor. The two articles together set the framing for the entire post-launch news cycle.
-----
James Alcott read Erik's article in the morning and felt the chill set in fully.
Until last night, he'd been holding onto the slim hope that Triton-1 would have functional weaknesses that would emerge under scrutiny. Sloppy execution. Inconsistent performance. Real-world reliability problems that didn't show up in a controlled launch demo.
Erik's article had drained that hope away. The reporting was thorough. The technology comparisons were grounded. The product was real, and it was going to consume the entire market.
Alcott's NeuraPath had spent four years and several hundred million dollars building a prosthetic that was now positioning to be a second-tier product in a market dominated by a converted-textile-workshop startup. The company that should have been the domestic benchmark had been demoted to an asterisk.
He could have wallowed. Instead, he opened a blank document and started drafting a pivot strategy. NeuraPath had assets that Triton-1 didn't directly compete with: medical relationships, surgical training programs, regulatory approvals already underway. Maybe NeuraPath could refocus on the patients who would still be candidates for surgical prosthetics: those for whom Triton-1's non-invasive approach didn't work due to specific neurological conditions. A niche, but a real one.
Or NeuraPath could try to license Triton-1's underlying technology and become a Prism Sciences distributor.
Or NeuraPath could pivot entirely. Surgical robotics. Rehabilitation devices. Brain-computer interfaces for non-prosthetic applications. The team had real expertise. The technology had alternative applications.
Alcott sketched the options. Each had risks. None of them involved leading the prosthetics market. He'd lost that opportunity permanently.
He saved the document and went to make breakfast. The crisis was permanent. The response started today.
-----
In Manhattan, Michael Reeve was already at his office.
His communications team had been assembled at three a.m. The Angel launch was scheduled for one p.m. Eastern. Ten hours away. Reeve had spent the past several hours doing what he always did when his strategy collapsed: rebuilding it from the ground up.
The original Angel positioning was no longer viable.
Triton-1 had captured every selling point Helios had been planning to highlight. Cutting-edge technology: Triton-1 was demonstrably ahead. Future of human augmentation: Triton-1 had already demonstrated the future. Compassionate accessibility: Triton-1 had priced itself at a tenth of Angel's expected retail. Stylish design: Triton-1's red flame motif and visible craftsmanship had photographed beautifully.
Helios had built a billion-dollar marketing campaign on talking points that no longer applied.
Reeve was sitting at the head of the conference table at four a.m., looking at his communications director, Karen Schmidt.
"What can we credibly emphasize that Triton-1 can't?"
Karen had been thinking about this since two a.m. "Three things. Premium materials and craftsmanship. Surgical integration. Established medical partnerships."
"Premium materials. Triton-1 looks fine. Are we genuinely better?"
"We use medical-grade materials throughout. Triton-1 uses titanium and standard polymers. We can credibly claim a more durable, longer-lasting product."
"Will the audience care?"
Karen's silence was the answer. The audience cared about whether the product worked, not what it was made of.
"Surgical integration. The pitch is what, exactly? Our product requires surgery and theirs doesn't?"
"We can frame surgery as commitment. As a serious medical procedure for patients who want the best possible outcome. The cap is convenient. Surgery is medicine."
Reeve thought about it. "That's spin."
"It's the only frame that turns our weakness into a strength."
"It also makes us sound condescending. 'Our product is better because it's harder to use.' That's not a winning message. The mass market is going to choose the easier option."
Karen sighed. "Then we focus on premium positioning. We position Angel as the high-end choice for patients who want the most advanced surgical-grade option, while acknowledging Triton-1 as a budget alternative. We accept that we're not the volume leader and that we capture a smaller, higher-margin market segment."
"That changes the entire investor pitch for the Series E. The funding round was predicated on Angel being the dominant brand. If we reposition as a niche premium product, the valuation premium evaporates."
"Yes."
The room was quiet.
Reeve looked at his cigar. He hadn't lit one yet today. The taste was wrong.
"Get me the partners on the line. We need to discuss whether to delay the Series E."
Karen stood up and walked to the phone bank.
The launch was still happening. The product would still ship. But the ambition behind the launch, the financial event Helios had been building toward for two years, was now being recalibrated in real time.
The cigar stayed in its case.
-----
Across town, near Times Square, the Prism Sciences showcase gallery was packed at midnight.
The gallery had opened the moment the domestic launch ended, accommodating the time zone difference. Holographic projectors weren't operating yet, since those units were limited to a domestic-market debut, but the demonstration prosthetics and full product information were available. NYPD officers stood at the entrance maintaining the queue, which extended around the block.
Inside, a Prism Sciences demonstration coordinator named Andy was managing the line.
"Demonstrations starting now. Please form a single line."
A teenager stood at the front of the queue. Fifteen years old, by Andy's estimation. He was looking at the suspended Triton-1 forearm prosthetic with an expression Andy had seen many times in his short career as a Prism Sciences employee: hunger.
The teenager's mother stood beside him.
Andy noticed that the boy's left forearm was held stiffly, unnaturally, and that he wore a glove on his left hand.
"Left forearm," Andy said. "Forearm prosthetic, then."
The boy nodded. Andy rolled the forearm Triton-1 over to the demonstration station and adjusted the connection. The boy put on the sensor cap, hands trembling slightly.
"Take your time. The signal acquisition takes a few moments to lock. Think about moving your left hand, any motion at all."
The boy stared at the prosthetic. Andy watched him. The mother watched him.
The crowd around the demonstration station went quiet, which was unusual for a midnight gallery in Manhattan.
The Triton-1 fingers twitched. Then closed. Then opened again. The prosthetic responded to the boy's neural signals with the same fluidity it had shown for every other user.
The boy's eyes widened.
"It works. It works."
He was speaking quietly, like he was afraid that saying it loudly would make it stop.
Phones around the demonstration station were already recording.
"Can I get one?" the boy asked Andy. "Today? Right now?"
Andy shook his head gently. "The fitting center isn't open in this market yet. Triton-1 ships through certified fitting centers, and we're still building the local center. It should open within the next few weeks. Once it does, you'll be able to schedule a fitting. There's no waitlist for individual orders, just the regulatory and licensing process."
The boy's face fell briefly. Then it brightened again.
"A few weeks?"
"A few weeks."
"That's nothing. I've been waiting nine years."
The crowd around the demonstration station applauded. Phone footage of the moment was uploaded to multiple platforms within minutes.
The video, which featured a teenager controlling a Triton-1 prosthetic for the first time, became the most-viewed clip of the night across major social platforms.
Comment threads exploded with reactions:
"Why doesn't my city have a Prism Sciences gallery? I want to feel what it's like to control a robot arm with my mind."
"Only a god could create technology like this."
"I'm starting to feel sorry for Helios. Their 'Angel' might be no match for the three-headed, six-armed mythological figure."
"If you're not crying watching this kid, you don't have a soul."
"Twelve hours until the Helios launch. Half of me wants to watch it burn. The other half doesn't want to make this kid wait three weeks for his arm because Helios sucked all the air out of the room."
The Prism Sciences logo on the gallery's window glowed softly through the late-night New York air. The line outside the gallery hadn't shortened. People had started bringing folding chairs.
The day was over for the company that had launched. The day was just starting for the company that had been launched against.
Twelve hours.
-----